In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine – an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission – is effective in reducing the drug resistance that nevirapine causes when used by itself. Such resistance can compromise later treatment regimens that include the same class of drug as nevirapine. The researchers report that the combination drug regimen — which involved the addition of a twice-daily dose of zidovudine and lamivudine over several days following a single-dose of nevirapine — is safe and easy to provide, and effective in reducing subsequent nevirapine resistance in both mothers and those babies that are infec ted despite antiretrovirals.
In a related Perspective, Dara Lehman (of Fred Hutchinson Cancer Research Center, Seattle, Washington) and colleagues, uninvolved with the research, say that assuming that there is not a large amount of lurking resistance not detected by the study, the approach may "strike the right balance of a feasible regimen that minimizes resistance" in resource-poor settings where combination antiretroviral therapy may not be available for longer-term use in pregnancy.
Funding: Boehringer Ingelheim, the developer and manufacturer of nevirapine, funded this trial, designed the study, was involved in data collection, and was responsible for data management and involved in the analysis. The decision to publish and preparation of the manuscript included employees of the sponsor, which gave an assurance that all authors have full access to the trial dataset.
Competing interests: M. Hopley, M. Ekelund, D. B. Hall, and P. Robinson are employed by Boehringer Ingelheim, the sponsor of the study, and D. Mayers was employed by Boehringer Ingelheim at the time of the study. Employees of the sponsor were involved in protocol design, were responsible for data management and statistical analyses, and assisted with the preparation of the paper. J. A. McIntyre and G. E. Gray have received research funding, travel grants and speaker's honoraria from Boehringer Ingelheim and Glaxo SmithKline. N. A. Martinson and D. Moodley declare no competing interests.
Citation: McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, et al. (2009) Efficacy of Short-Course AZT Plus 3TC to Reduce Nevirapine Resistance in the Prevention of Mother-to-Child HIV Transmission: A Randomized Clinical Trial. PLoS Med 6(10): e1000172. doi:10.1371/journal.pmed.1000172
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000172
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-10-martinson.pdf
CONTACT:
Neil Martinson
Perinatal HIV Research Unit
Johns Hopkins University School of Medicine
Chris Hani Baragwanath Hospital
Old Potch Rd
Soweto, Gauteng Province 1864
South Africa
+27119899703
+27119899762 (fax)
martinson@hivsa.com
Related PLoS Medicine Perspective:
Funding: No specific funding was received for this article.
Competing Interests: The authors have declared that no competing interests exist.
Citation: Lehman DA, John-Stewart GC, Overbaugh J (2009) Antiretroviral Strategies to Prevent Mother-to-Child Transmission of HIV: Striking a Balance between Efficacy, Feasibility, and Resistance. PLoS Med 6(10):e1000169. doi:10.1371/journal.pmed.1000169
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000169
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-10-lehman.pdf
CONTACT:
Dara Lehman
University of Washington
Molecular and Cellular Biology
Seattle, 98104
United States of America
dlehman@u.washington.edu
Journal
PLoS Medicine